Targeted therapy cancer brands to achieve sales of over $42 billion by 2017Targeted therapies have improved treatment outcomes in cancer …
Novartis has shaken up its senior management structure with the creation of a new post – chief operating officer. From …
Merck has announced a new round of job cuts and restructuring in a bid to update its business model and …
Roche's sales dropped 2% to 33.3 billion Swiss francs in the first nine months of 2008, due to a sharp …
Bioscience leaders from both sides of the Atlantic have joined in a war game that could help boost the UK …
Talks on the future of pharmaceutical pricing scheme the PPRS have stumbled into trouble, after it emerged a major part …
The relationship between doctors and the pharmaceutical industry has attracted considerable criticism in the past five years. Scepticism has risen, …
Opportunity knocks for big pharmaceutical companies in the credit crunchAlthough the credit crunch has left non-financial services companies, including those …
Pfizer is repackaging its medicines in a bid to make dosing instructions clearer. The National Patient Safety Agency (NPSA) estimates …
The Healthcare Commission's third yearly snapshot of the NHS in England shows a significant increase in trusts performing well, but …
MedImmune, AstraZeneca's biotech arm, has opened a new R&D facility in Cambridge as part of a major expansion of its …
Daiichi-Sankyo and Lilly have responded to media speculation around the FDA's make-or-break ruling on their major new drug prasugrel. The …
The government is investing £5 million in specialist research projects on the planning and provision of health services. The new …
The European future of Wyeth’s depression treatment Ellefore has been thrown into doubt after the pharma company withdrew its application …
GlaxoSmithKline has extended its reach into emerging markets by acquiring Bristol-Myers Squibb’s Egyptian mature products business for £125 millionThe move …
Contract research organisations are now play a key role in the development of most of the industry's drugs, with some …
NICE has spurned GSK's risk-sharing proposal for its breast cancer treatment Tyverb, saying the drug is still too expensive to …
Oxford BioMedica has settled on a permanent chief executive, promoting John Dawson from his acting leadership position. Chairman professor Alan …